Roblitinib

ALTERNATE NAMES: FGF401; N-[5-cyano-4-(2-methoxyethlamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-[5-cyano-4-[(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

CATALOG #: B3008-1 1 mg  B3008-5 5 mg

STRUCTURE:

MOLECULAR FORMULA: C₂₅H₃₀N₈O₄

MOLECULAR WEIGHT: 506.6

CAS NUMBER: 1708971-55-4

APPEARANCE: Pale-yellow Solid

PURITY: >98%

SOLUBILITY: ~5 mg/ml in DMSO (gently warm and vortex)

DESCRIPTION: Roblitinib is a reversible-covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) tyrosine kinase. It shows 1000-fold selectivity for FGFR4 over FGFR1/2/3 and other kinases, with an IC₅₀ value of 1.9 nM against FGFR4. It shows potent antitumor activity in mice bearing Hepatocellular carcinoma (HCC) tumor xenografts and patient-derived tumor xenograft PDX models. It has entered phase I/II clinical trials to evaluate its safety and efficacy in HCC and other solid tumors. It leads to upregulation of bile acid synthesis and a subsequent increase in ALT expression in preclinical studies, which can be prevented by combination with the bile acid sequestrant cholestyramine.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.


DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.